These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

236 related articles for article (PubMed ID: 27941799)

  • 1. Inhibition of Notch pathway arrests PTEN-deficient advanced prostate cancer by triggering p27-driven cellular senescence.
    Revandkar A; Perciato ML; Toso A; Alajati A; Chen J; Gerber H; Dimitrov M; Rinaldi A; Delaleu N; Pasquini E; D'Antuono R; Pinton S; Losa M; Gnetti L; Arribas A; Fraering P; Bertoni F; Nepveu A; Alimonti A
    Nat Commun; 2016 Dec; 7():13719. PubMed ID: 27941799
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeting notch pathway enhances rapamycin antitumor activity in pancreas cancers through PTEN phosphorylation.
    Vo K; Amarasinghe B; Washington K; Gonzalez A; Berlin J; Dang TP
    Mol Cancer; 2011 Nov; 10():138. PubMed ID: 22074495
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Vulnerabilities of PTEN-TP53-deficient prostate cancers to compound PARP-PI3K inhibition.
    González-Billalabeitia E; Seitzer N; Song SJ; Song MS; Patnaik A; Liu XS; Epping MT; Papa A; Hobbs RM; Chen M; Lunardi A; Ng C; Webster KA; Signoretti S; Loda M; Asara JM; Nardella C; Clohessy JG; Cantley LC; Pandolfi PP
    Cancer Discov; 2014 Aug; 4(8):896-904. PubMed ID: 24866151
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Notch promotes tumor metastasis in a prostate-specific Pten-null mouse model.
    Kwon OJ; Zhang L; Wang J; Su Q; Feng Q; Zhang XH; Mani SA; Paulter R; Creighton CJ; Ittmann MM; Xin L
    J Clin Invest; 2016 Jul; 126(7):2626-41. PubMed ID: 27294523
    [TBL] [Abstract][Full Text] [Related]  

  • 5. 1,25-dihydroxyvitamin D(3) and PI3K/AKT inhibitors synergistically inhibit growth and induce senescence in prostate cancer cells.
    Axanova LS; Chen YQ; McCoy T; Sui G; Cramer SD
    Prostate; 2010 Nov; 70(15):1658-71. PubMed ID: 20583132
    [TBL] [Abstract][Full Text] [Related]  

  • 6. New insights into Notch1 regulation of the PI3K-AKT-mTOR1 signaling axis: targeted therapy of γ-secretase inhibitor resistant T-cell acute lymphoblastic leukemia.
    Hales EC; Taub JW; Matherly LH
    Cell Signal; 2014 Jan; 26(1):149-61. PubMed ID: 24140475
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Notch-1 signaling is lost in prostate adenocarcinoma and promotes PTEN gene expression.
    Whelan JT; Kellogg A; Shewchuk BM; Hewan-Lowe K; Bertrand FE
    J Cell Biochem; 2009 Aug; 107(5):992-1001. PubMed ID: 19479935
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Activation of nuclear PTEN by inhibition of Notch signaling induces G2/M cell cycle arrest in gastric cancer.
    Kim SJ; Lee HW; Baek JH; Cho YH; Kang HG; Jeong JS; Song J; Park HS; Chun KH
    Oncogene; 2016 Jan; 35(2):251-60. PubMed ID: 25823029
    [TBL] [Abstract][Full Text] [Related]  

  • 9. PTEN regulates sensitivity of melanoma cells to RO4929097, the γ-secretase inhibitor.
    Nair JS; Sheikh T; Ho AL; Schwartz GK
    Anticancer Res; 2013 Apr; 33(4):1307-16. PubMed ID: 23564767
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Acute T-cell leukemias remain dependent on Notch signaling despite PTEN and INK4A/ARF loss.
    Medyouf H; Gao X; Armstrong F; Gusscott S; Liu Q; Gedman AL; Matherly LH; Schultz KR; Pflumio F; You MJ; Weng AP
    Blood; 2010 Feb; 115(6):1175-84. PubMed ID: 20008304
    [TBL] [Abstract][Full Text] [Related]  

  • 11. NOTCH and PTEN in prostate cancer.
    Bertrand FE; McCubrey JA; Angus CW; Nutter JM; Sigounas G
    Adv Biol Regul; 2014 Sep; 56():51-65. PubMed ID: 24933481
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Active notch protects MAPK activated melanoma cell lines from MEK inhibitor cobimetinib.
    Porcelli L; Mazzotta A; Garofoli M; Di Fonte R; Guida G; Guida M; Tommasi S; Azzariti A
    Biomed Pharmacother; 2021 Jan; 133():111006. PubMed ID: 33202284
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Skp2 targeting suppresses tumorigenesis by Arf-p53-independent cellular senescence.
    Lin HK; Chen Z; Wang G; Nardella C; Lee SW; Chan CH; Yang WL; Wang J; Egia A; Nakayama KI; Cordon-Cardo C; Teruya-Feldstein J; Pandolfi PP
    Nature; 2010 Mar; 464(7287):374-9. PubMed ID: 20237562
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Re-education of Tumor-Associated Macrophages by CXCR2 Blockade Drives Senescence and Tumor Inhibition in Advanced Prostate Cancer.
    Di Mitri D; Mirenda M; Vasilevska J; Calcinotto A; Delaleu N; Revandkar A; Gil V; Boysen G; Losa M; Mosole S; Pasquini E; D'Antuono R; Masetti M; Zagato E; Chiorino G; Ostano P; Rinaldi A; Gnetti L; Graupera M; Martins Figueiredo Fonseca AR; Pereira Mestre R; Waugh D; Barry S; De Bono J; Alimonti A
    Cell Rep; 2019 Aug; 28(8):2156-2168.e5. PubMed ID: 31433989
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Enhancing chemotherapy efficacy in Pten-deficient prostate tumors by activating the senescence-associated antitumor immunity.
    Toso A; Revandkar A; Di Mitri D; Guccini I; Proietti M; Sarti M; Pinton S; Zhang J; Kalathur M; Civenni G; Jarrossay D; Montani E; Marini C; Garcia-Escudero R; Scanziani E; Grassi F; Pandolfi PP; Catapano CV; Alimonti A
    Cell Rep; 2014 Oct; 9(1):75-89. PubMed ID: 25263564
    [TBL] [Abstract][Full Text] [Related]  

  • 16. HepaCAM inhibits the malignant behavior of castration-resistant prostate cancer cells by downregulating Notch signaling and PF-3084014 (a γ-secretase inhibitor) partly reverses the resistance of refractory prostate cancer to docetaxel and enzalutamide in vitro.
    Du Z; Li L; Sun W; Wang X; Zhang Y; Chen Z; Yuan M; Quan Z; Liu N; Hao Y; Li T; Wang J; Luo C; Wu X
    Int J Oncol; 2018 Jul; 53(1):99-112. PubMed ID: 29658567
    [TBL] [Abstract][Full Text] [Related]  

  • 17. NFATc1 promotes prostate tumorigenesis and overcomes PTEN loss-induced senescence.
    Manda KR; Tripathi P; Hsi AC; Ning J; Ruzinova MB; Liapis H; Bailey M; Zhang H; Maher CA; Humphrey PA; Andriole GL; Ding L; You Z; Chen F
    Oncogene; 2016 Jun; 35(25):3282-92. PubMed ID: 26477312
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Regulation of PTEN by CK2 and Notch1 in primary T-cell acute lymphoblastic leukemia: rationale for combined use of CK2- and gamma-secretase inhibitors.
    Silva A; Jotta PY; Silveira AB; Ribeiro D; Brandalise SR; Yunes JA; Barata JT
    Haematologica; 2010 Apr; 95(4):674-8. PubMed ID: 20015880
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of selective gamma-secretase inhibitor PF-03084014 for its antitumor efficacy and gastrointestinal safety to guide optimal clinical trial design.
    Wei P; Walls M; Qiu M; Ding R; Denlinger RH; Wong A; Tsaparikos K; Jani JP; Hosea N; Sands M; Randolph S; Smeal T
    Mol Cancer Ther; 2010 Jun; 9(6):1618-28. PubMed ID: 20530712
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Crucial role of p53-dependent cellular senescence in suppression of Pten-deficient tumorigenesis.
    Chen Z; Trotman LC; Shaffer D; Lin HK; Dotan ZA; Niki M; Koutcher JA; Scher HI; Ludwig T; Gerald W; Cordon-Cardo C; Pandolfi PP
    Nature; 2005 Aug; 436(7051):725-30. PubMed ID: 16079851
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.